| part | subject | predicate | object | published by | date | |
|---|---|---|---|---|---|---|
|
Assertion
|
|
|||||
|
Assertion
|
TCAs can serve as first-line or augmenting drugs for neuropathic pain, headache, migraine, gastrointestinal syndromes, fibromyalgia, pelvic pain, insomnia, and psychiatric conditions other than depression.
|
|
||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|
|||||
|
Assertion
|
|